News|Articles|November 5, 2014

Vaccine Strategies in Follicular Lymphoma

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma.

Clinical Pearls

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma. Brody presented on this topic at the 2014 Chemotherapy Foundation Symposium.

First generations of lymphoma vaccines looked promising, but were not efficacious enough to become standard therapies.
New lymphoma vaccines take a more holistic perspective targeting any tumor-specific or tumor-associated antigens.

<<<

Stay up to date on practice-changing data in community practice.

Vaccine Strategies in Follicular Lymphoma

Clinical Pearls

Related Content

Life Years Saved: Why This Metric Better Reflects Progress in Blood Cancer

DISC-3405 Reduces Phlebotomy Burden in Polycythemia Vera

Expanding Blood Cancer Care With the Next Frontier of T-Cell Immunotherapy

Strategies Shift Beyond Traditional Management of Immune Thrombocytopenia

Fixed-Duration Mosun-Pola Yields High ORR in R/R Mantle Cell Lymphoma

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Louisiana Oncology Society

Nevada Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Wisconsin Association of Hematology and Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Final Approval to Cabozantinib Capsule Formulation

FDA Delays Decision on Zanzalintinib Combo for mCRC

Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma

Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care

Adults With Disabilities Face Gaps in Breast, Cervical, Colorectal Cancer Screening